+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Central Nervous System Disorders Therapeutics Market 2021-2025

  • PDF Icon

    Report

  • 120 Pages
  • June 2021
  • Region: Global
  • TechNavio
  • ID: 5204155
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher has been monitoring the central nervous system disorders therapeutics market and it is poised to grow by $ 24.35 bn during 2021-2025, progressing at a CAGR of 4.44% during the forecast period. Our report on the central nervous system disorders therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.



The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of CNS disorders and special regulatory designations for CNS disorders.



The central nervous system disorders therapeutics market analysis includes the type segment and geographic landscape.



The central nervous system disorders therapeutics market is segmented as below:


By Type


  • Depression drugs
  • Multiple sclerosis drugs
  • Schizophrenia drugs
  • Bipolar disorder therapeutics
  • Epilepsy drugs
  • Others

By Geography


  • Europe
  • North America
  • Asia
  • ROW

This study identifies the increasing awareness programs as one of the prime reasons driving the central nervous system disorders therapeutics market growth during the next few years. Also, will lead to sizable demand in the market.



The report on central nervous system disorders therapeutics market covers the following areas:

  • Central nervous system disorders therapeutics market sizing
  • Central nervous system disorders therapeutics market forecast
  • Central nervous system disorders therapeutics market industry analysis

The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading central nervous system disorders therapeutics market vendors that include AstraZeneca Plc, Boehringer Ingelheim International GmbH, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Inc., Merck and Co. Inc., Novartis AG, Otsuka Holdings Co. Ltd., and Pfizer Inc. Also, the central nervous system disorders therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.



The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape



The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.


Table of Contents

Executive Summary
  • Market Overview

Market Landscape
  • Market ecosystem
  • Value chain analysis

Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type
  • Market segments
  • Comparison by Type
  • Depression drugs - Market size and forecast 2020-2025
  • Multiple sclerosis drugs - Market size and forecast 2020-2025
  • Schizophrenia drugs - Market size and forecast 2020-2025
  • Bipolar disorder therapeutics - Market size and forecast 2020-2025
  • Epilepsy drugs - Market size and forecast 2020-2025
  • Others - Market size and forecast 2020-2025
  • Market opportunity by Type

Customer landscape
Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • Europe - Market size and forecast 2020-2025
  • North America - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape
  • Landscape disruption

Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Johnson and Johnson Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.

Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

List of Exhibits
  • Key Finding 1
  • Key Finding 2
  • Key Finding 3
  • Key Finding 5
  • Key Finding 6
  • Key Finding 7
  • Key Finding 8
  • Parent market
  • Market characteristics
  • Offerings of vendors included in the market definition
  • Market segments
  • Global - Market size and forecast 2020 - 2025 ($ million)
  • Global market: Year-over-year growth 2020 - 2025 (%)
  • Five forces analysis 2020 & 2025
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition - Five forces 2020
  • Type - Market share 2020-2025 (%)
  • Comparison by Type
  • Depression drugs - Market size and forecast 2020-2025 ($ million)
  • Depression drugs - Year-over-year growth 2020-2025 (%)
  • Multiple sclerosis drugs - Market size and forecast 2020-2025 ($ million)
  • Multiple sclerosis drugs - Year-over-year growth 2020-2025 (%)
  • Schizophrenia drugs - Market size and forecast 2020-2025 ($ million)
  • Schizophrenia drugs - Year-over-year growth 2020-2025 (%)
  • Bipolar disorder therapeutics - Market size and forecast 2020-2025 ($ million)
  • Bipolar disorder therapeutics - Year-over-year growth 2020-2025 (%)
  • Epilepsy drugs - Market size and forecast 2020-2025 ($ million)
  • Epilepsy drugs - Year-over-year growth 2020-2025 (%)
  • Others - Market size and forecast 2020-2025 ($ million)
  • Others - Year-over-year growth 2020-2025 (%)
  • Market opportunity by Type
  • Customer landscape
  • Market share by geography 2020-2025 (%)
  • Geographic comparison
  • Europe - Market size and forecast 2020-2025 ($ million)
  • Europe - Year-over-year growth 2020-2025 (%)
  • North America - Market size and forecast 2020-2025 ($ million)
  • North America - Year-over-year growth 2020-2025 (%)
  • Asia - Market size and forecast 2020-2025 ($ million)
  • Asia - Year-over-year growth 2020-2025 (%)
  • ROW - Market size and forecast 2020-2025 ($ million)
  • ROW - Year-over-year growth 2020-2025 (%)
  • Key leading countries
  • Market opportunity by geography ($ million)
  • Impact of drivers and challenges
  • Vendor landscape
  • Landscape disruption
  • Industry risks
  • Vendors covered
  • Market positioning of vendors
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Product and service
  • AstraZeneca Plc - Key offerings
  • AstraZeneca Plc - Key customers
  • AstraZeneca Plc - Segment focus
  • Boehringer Ingelheim International GmbH - Overview
  • Boehringer Ingelheim International GmbH - Business segments
  • Boehringer Ingelheim International GmbH - Key offerings
  • Boehringer Ingelheim International GmbH - Key customers
  • Boehringer Ingelheim International GmbH - Segment focus
  • Eli Lilly and Co. - Overview
  • Eli Lilly and Co. - Business segments
  • Eli Lilly and Co. - Key offerings
  • Eli Lilly and Co. - Key customers
  • Eli Lilly and Co. - Segment focus
  • F. Hoffmann-La Roche Ltd. - Overview
  • F. Hoffmann-La Roche Ltd. - Business segments
  • F. Hoffmann-La Roche Ltd. - Key offerings
  • F. Hoffmann-La Roche Ltd. - Key customers
  • F. Hoffmann-La Roche Ltd. - Segment focus
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Key customers
  • GlaxoSmithKline Plc - Segment focus
  • Johnson and Johnson Inc. - Overview
  • Johnson and Johnson Inc. - Business segments
  • Johnson and Johnson Inc. - Key offerings
  • Johnson and Johnson Inc. - Key customers
  • Johnson and Johnson Inc. - Segment focus
  • Merck and Co. Inc. - Overview
  • Merck and Co. Inc. - Business segments
  • Merck and Co. Inc. - Key offerings
  • Merck and Co. Inc. - Key customers
  • Merck and Co. Inc. - Segment focus
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key offerings
  • Novartis AG - Key customers
  • Novartis AG - Segment focus
  • Otsuka Holdings Co. Ltd. - Overview
  • Otsuka Holdings Co. Ltd. - Business segments
  • Otsuka Holdings Co. Ltd. - Key offerings
  • Otsuka Holdings Co. Ltd. - Key customers
  • Otsuka Holdings Co. Ltd. - Segment focus
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Key customers
  • Pfizer Inc. - Segment focus
  • Currency conversion rates for US$
  • Research Methodology
  • Validation techniques employed for market sizing
  • Information sources
  • List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global central nervous system disorders therapeutics market: AstraZeneca Plc, Boehringer Ingelheim International GmbH, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Inc., Merck and Co. Inc., Novartis AG, Otsuka Holdings Co. Ltd., and Pfizer Inc.

Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is increasing awareness programs.`

According to the report, one of the major drivers for this market is the increasing prevalence of CNS disorders.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson and Johnson Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.